Rose Berman
Family Medicine · Long Beach, CANPI 1225113830
Payments from drug & device makers
Across 137 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$325
- Bristol Myers Squibb$232
- EMD Serono, Inc.$195
- Eisai Inc.$158
- Teva Pharmaceuticals USA, Inc.$98
- plus $555 from 12 others
What the payments were for
- Food & beverage$2,679100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $1,117 |
| Novartis | 19 | $325 |
| Bristol Myers Squibb | 10 | $232 |
| EMD Serono, Inc. | 11 | $195 |
| Eisai Inc. | 6 | $158 |
| Teva Pharmaceuticals USA, Inc. | 5 | $98 |
| Genentech USA, Inc. | 4 | $90 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $90 |
| Johnson & Johnson | 5 | $87 |
| Biogen | 3 | $62 |
| Acadia Pharmaceuticals Inc | 2 | $49 |
| MDD US Operations, LLC | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| UCB, Inc. | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $25 |
| SK Life Science, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
How this compares
$2,679 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 15 | $173,504 |
| Avonex (4 Pack)Interferon Beta-1a | 20 | $161,551 |
| GlatopaGlatiramer Acetate | 15 | $44,381 |
| Nurtec OdtRimegepant Sulfate | 15 | $20,230 |
| Memantine Hcl | 96 | $5,566 |
| Gabapentin | 133 | $2,591 |
| Lacosamide | 21 | $2,021 |
| Donepezil Hcl | 149 | $1,784 |
| Divalproex Sodium | 16 | $1,648 |
| Levetiracetam | 52 | $1,507 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 36 | $1,020 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 31 | $956 |
| Pregabalin | 18 | $769 |
| Quetiapine Fumarate | 46 | $763 |
| Baclofen | 25 | $681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $62 | $161,55120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Long Beach
- Steven ReynoldsLong Beach$53M
- Jack VuLong Beach$10.1M
- Amina HaggagNorthridge$112.8M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.